Prognostic factors in Hodgkin's disease (Q62096688)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Prognostic factors in Hodgkin's disease (English)

0 references

Prognostic Factors in Hodgkin's Disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1

Lena Specht

0 references

publication date

July 1996

0 references

1 July 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

Seminars in Radiation Oncology

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

146-161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10717174%20AND%20SRC:MED&resulttype=core&format=json

Problems with using observational databases to compare treatments

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The American Joint Committee on Cancer. Criteria for prognostic factors and for an enhanced prognostic system.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

[PROPOSAL OF CLASSIFICATION AND THERAPY OF HODGKIN'S DISEASE]

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Cure of Hodgkin's Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Malignant lymphomas: classification, prognosis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The Prognosis in Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Survival in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Therapy results in Hodgkin's disease Freiburg i.Br., 1948-1966

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Improved survival in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease prognosis: a directly predictive equation.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

National survey of patterns of care for Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease. A clinical and pathologic study of 235 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic groups for management of localized Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The role of prognostic factors in treatment selection for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Tumor burden as the most important prognostic factor in early stage Hodgkin's disease.Relations to other prognostic factors and implications for choice of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Bulky mediastinal Hodgkin's disease management and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Influence on response to therapy and overall survival of mediastinal involvement by Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of large mediastinal involvement in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartholomew's Hospital. A retrospective review of 114 previously untreated patients over 14 years

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of mediastinal mass in adult Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage IA to IIB mediastinal Hodgkin's disease: three-dimensional volumetric assessment of response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Importance of initial mediastinal adenopathy in Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Thoracic irradiation in Hodgkin's disease: disease control and long-term complications

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radiotherapy results in laparotomy-staged Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease in young and elderly patients. Clinical and pathological studies. Minireview based on a doctoral thesis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The management of localized, infradiaphragmatic Hodgkin's disease: experience of a rare clinical presentation at St Bartholomew's Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease, stages I and II occurring below the diaphragm

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease presenting below the diaphragm: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors in patients with subdiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Therapy and prognosis of two different forms of organ involvement in cases of malignant lymphoma (Hodgkin's disease, reticulum cell sarcoma, lymphosarcoma) as well as a report about stage division in these diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Limited extranodal Hodgkin's disease. Unfavorable prognosis and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Is it an E lesion or stage IV? An unsettled issue in Hodgkin's disease staging

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The Ann Arbor staging system for Hodgkin's disease: Does E stand for error?

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease: a clinicopathologic study of 659 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

1 reference

7 January 2021

Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

New assessment of the prognostic significance of histopathology in Hodgkin's disease for laparotomy-negative stage I and stage II patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Analysis of grade 1 Hodgkin's disease (Report no 6)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Histologic Subclassification of Nodular Sclerosis Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A clinicopathological study of nodular sclerosing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Correlation of histopathology with other prognostic indicators in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Nodular and diffuse types of lymphocyte predominance Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Lymphocyte predominant Hodgkin's disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radiotherapy of stage I and II Hodgkin's disease. A collaborative study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease in patients over sixty years old

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic indicators in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

An analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A multivariate analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The prognostic significance of age in Hodgkin's disease: examination of 1500 patients (BNLI report no. 23)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors in Hodgkin's disease with special reference to age

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Survival of the older patient compared with the younger patient with Hodgkin's disease. Influence of histologic type, staging, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Treatment outcome in Hodgkin's disease in patients above the age of 60: A population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Systemic treatment of cancer in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage IIB Hodgkin's disease: the Stanford experience

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 30).

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors for positive surgical staging in patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Predicting the risk of abdominal disease in Hodgkin's lymphoma. A multifactorial analysis of staging laparotomy results in 255 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Individual risk of abdominal disease in patients with stages I and II supradiaphragmatic Hodgkin's disease. A rule index based on 341 laparotomized patients

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum albumin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The therapeutic implications of splenic involvement in stage IIIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Patterns of relapse in stages I, II and IIIA Hodgkin's disease: Influence of initial therapy and implications for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Stage III Hodgkin's disease--long-term results following chemotherapy, radiotherapy and combined modality therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Reassessment of prognostic factors in stage IIIA and IIIB Hodgkin's disease treated with MOPP and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors in pathological stage IIIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic significance of lymphography in stage IIIs Hodgkin's disease (HD)

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

[Chemotherapy of advanced lymphogranulomatosis. Results of MOPP/COPP treatment at the West German Tumor Center, Essen]

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Assessment of bone marrow histology in Hodgkin's disease: correlation with clinical factors

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

MVPP chemotherapy regimen for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Hodgkin's disease: Combination chemotherapy for relapse following radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors for patients with Hodgkin disease in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in hodgkin's disease. An analysis of long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Prolonged Disease-Free Survival in Hodgkin's Disease with MOPP Reinduction After First Relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Late relapses in Hodgkin's disease: outcome of patients relapsing more than twelve months after primary chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radiation therapy salvage of Hodgkin's disease following chemotherapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Salvage radiotherapy following chemotherapy failure in Hodgkin's disease--what is its role?

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Intensive therapy and autotransplantation in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum cytokine levels correlate with clinical parameters in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The Clinical Significance of Cytokines and Soluble Forms of Membrane-Derived Activation Antigens in the Serum of Patients with Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

The clinical Significance of serum CD8 antigen levels in adult patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2896%2980012-9

7 January 2021

10.1016/S1053-4296(96)80012-9

Identifiers

DOI

0 references

1 reference